Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 4/20 | 0.43 |
| ▸ | CA1 | P00915 | 4/20 | 0.43 |
| ▸ | CA2 | P00918 | 4/20 | 0.43 |
| ▸ | CA4 | P22748 | 4/20 | 0.43 |
| ▸ | CA9 | Q16790 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.32 |
| ▸ | PDE5A | O76074 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9335142 | 1.00 | CA12 (0.43) | CA12CA1CA2CA4CA9 | |
| SCHEMBL28750843 | 1.00 | CA12 (0.43) | CA12CA1CA2CA4CA9 | |
| SCHEMBL3993199 | 1.00 | CA12 (0.43) | CA12CA1CA2CA4CA9 | |
| SCHEMBL3990507 | 0.98 | — | — | |
| SCHEMBL1041500 | 0.90 | — | — | |
| SCHEMBL25180667 | 0.87 | CA12 (0.50) | CA12CA1CA2CA4CA9 | |
| SCHEMBL324868 | 0.87 | CA12 (0.50) | CA12CA1CA2CA4CA9 | |
| SCHEMBL25180691 | 0.87 | CA12 (0.50) | CA12CA1CA2CA4CA9 | |
| SCHEMBL8957343 | 0.87 | CA12 (0.50) | CA12CA1CA2CA4CA9 | |
| SCHEMBL1842696 | 0.87 | CA12 (0.50) | CA12CA1CA2CA4CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0207674-A2 | 1,4-Dihydropyridine derivatives, their preparation and their pharmaceutical use | SANKYO COMPANY LIMITED (JP) | 1987-01-07 | — | — | EP | claimed |
| EP-2250164-A2 | ANGIOTENSIN II RECEPTOR BLOCKER DERIVATIVES | Nicox S.A. (FR) | 2010-11-17 | — | — | EP | disclosed |
| WO-2009106471-A2 | NEW ANGIOTENSIN II RECEPTOR BLOCKER DERIVATIVES | NICOX S.A. (FR) | 2009-09-03 | — | — | WO | disclosed |
| EP-1601644-B1 | NITRIC OXIDE RELEASING PRODRUGS OF DIARYL-2-(5H)-FURANONES AS CYCLOOXYGENASE-2 INHIBITORS | MERCK FROSST COMPANY (CA) | 2009-05-27 | — | — | EP | disclosed |
| US-20070179150-A1 | NITROSATED PROTON PUMP INHIBITORS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2007-08-02 | — | — | US | disclosed |
| US-7211590-B2 | Nitrosated proton pump inhibitors, compositions and methods of use | NITROMED, INC. (US) | 2007-05-01 | — | — | US | disclosed |
| US-7169809-B2 | Nitric oxide releasing prodrugs of diaryl-2-(5H)-furanones as cyclooxygenase-2 inhibitors | MERCK FROSST COMPANY (CA) | 2007-01-30 | — | — | US | disclosed |
| EP-1534278-A4 | NITROSATED PROTON PUMP INHIBITORS, COMPOSITIONS AND METHODS OF USE | NITROMED INC (US) | 2006-09-06 | — | — | EP | disclosed |
| EP-1601644-A1 | NITRIC OXIDE RELEASING PRODRUGS OF DIARYL-2-(5H)-FURANONES AS CYCLOOXYGENASE-2 INHIBITORS | Merck Frosst Canada & Co. (CA) | 2005-12-07 | — | — | EP | disclosed |
| EP-1534278-A2 | NITROSATED PROTON PUMP INHIBITORS, COMPOSITIONS AND METHODS OF USE | Nitromed, Inc. (US) | 2005-06-01 | — | — | EP | disclosed |
| WO-2004103955-A1 | NITRIC OXIDE RELEASING PRODRUGS OF DIARYL-2-(5H)-FURANONES AS CYCLOOXYGENASE-2 INHIBITORS | MERCK FROSST COMPANY (CA) | 2004-12-02 | — | — | WO | disclosed |
| US-20040176331-A1 | Nitric oxide releasing prodrugs of diaryl-2-(5H)-furanones as cyclooxygenase-2 inhibitors | MERCK FROSST COMPANY (CA) | 2004-09-09 | — | — | US | disclosed |
| WO-2004012659-A2 | NITROSATED PROTON PUMP INHIBITORS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2004-02-12 | — | — | WO | disclosed |
| WO-2004011421-A1 | NITRIC OXIDE RELEASING PRODRUGS OF DIARYL-2-(5H)-FURANONES AS CYCLOOXYGENASE-2 INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 2004-02-05 | — | — | WO | disclosed |
| US-20040024014-A1 | Nitrosated proton pump inhibitors, compositions and methods of use | NITROMED, INC. (US) | 2004-02-05 | — | — | US | disclosed |
| EP-0361888-B1 | Apovincaminic acid derivatives | TAISHO PHARMACEUTICAL CO LTD (JP) | 1994-05-04 | — | — | EP | disclosed |
| US-4992451-A | Hypotensive agents, calcium blocking agents | SANKYO COMPANY, LIMITED (JP) | 1991-02-12 | — | — | US | disclosed |
| US-4980474-A | For treatment of vascular injuries, angina pectoris, hypertension and alzheimer*s disease | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 1990-12-25 | — | — | US | disclosed |
| EP-0361888-A2 | Apovincaminic acid derivatives | TAISHO PHARMACEUTICAL CO. LTD (JP) | 1990-04-04 | — | — | EP | disclosed |
| EP-0207674-A2 | 1,4-Dihydropyridine derivatives, their preparation and their pharmaceutical use | SANKYO COMPANY LIMITED (JP) | 1987-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176331-A1 | Nitric oxide releasing prodrugs of diaryl-2-(5H)-furanones as cyclooxygenase-2 inhibitors | PTGIS, PTGS1, PTGS2 | CA12 4091/4885CA1 2787/4885CA2 1084/4885 |
| US-20070179150-A1 | NITROSATED PROTON PUMP INHIBITORS, COMPOSITIONS AND METHODS OF USE | NOS1, PTGS1, NOS2 | CA12 3619/4885CA1 2157/4885CA2 843/4885 |
| US-20040024014-A1 | Nitrosated proton pump inhibitors, compositions and methods of use | NOS1, PTGS1, NOS2 | CA12 3619/4885CA1 2157/4885CA2 843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.